In a major advancement for allergy emergency care, the U.S. Food and Drug Administration (FDA) approved neffy®, a 2 mg epinephrine nasal spray, in August 2024. This marked the first-ever needle-free treatment option for anaphylaxis, available by prescription for adults and children weighing at least 66 pounds.

neffy® is administered as a nasal spray, providing a rapid and convenient alternative to epinephrine auto-injectors. Its needle-free design may reduce hesitation during emergencies and improve timely use among patients and caregivers.

Clinical trials have shown that neffy® delivers epinephrine levels comparable to injection-based devices, with similar cardiovascular responses, such as increased heart rate and blood pressure.

Expanding on its initial approval, the FDA in March 2025 approved a 1 mg neffy® nasal spray for children ages 4 and older who weigh between 33 and 66 pounds. This new formulation is expected to become available for prescription in May 2025, further broadening access to this innovative emergency treatment.

With both dosage options now FDA-approved, neffy® offers a safe and user-friendly option for more individuals at risk of severe allergic reactions. However, it remains essential that patients always carry their prescribed epinephrine and seek immediate medical attention following use.

For more information, click here.